Therapeutic Potential of Secretome-Derived Wharton's Jelly Mesenchymal Stem Cells in Psoriasis Vulgaris: A Case Study
Abstract
Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Case: In this report, we discuss our findings about a 47-years old psoriasis suffering male patient with a Psoriasis Area Severity Index (PASI) score of 10.8, treated with Wharton’s Jelly Mesenchymal Stem Cells-derived Secretome (S-MSCs). Remarkably, complete regression was recorded within a treatment period of a week only. Result: The patient demonstrated a decrease in PASI, from 10.8 to 3.2 after 1 infusion and followed by 4 intramuscular injections of S-MSCs. Bioactive factors secreted by MSCs, cytokines and growth factors, are very likely to be the principal molecules which play a vital role in inflammatory modulation and skin tissue regeneration. No serious adverse events were noted for the patient as a result of secretome infusion and intramuscular injection. Conclusion: This report demonstrates safety and promises to be an effective strategy using S-MSCs treatment for managing the psoriatic issue and, thus, may offer as an alternative approach to overcome the limitations of the cell-based therapy.
References
Kanda N. Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated. Int J Mol Sci [Internet]. 2021 Mar 2 [cited 2024 Jul 25];22(6):1–5. Available from: /pmc/articles/PMC8000092/
Yamazaki F. Psoriasis: Comorbidities. J Dermatol [Internet]. 2021 Jun 1 [cited 2024 Jul 31];48(6):732–40. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.15840
Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: A review. J Dermatol [Internet]. 2021 Jun 1 [cited 2024 Jul 31];48(6):722–31. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.15913
Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017 Dec 1;49:1–8.
Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021 Jun 1;47(6).
Raut G, Wairkar S. Management of psoriasis with nutraceuticals: An update. Complement Ther Clin Pract. 2018 May 1;31:25–30.
Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: The role of T regulatory cells. Immunology. 2006;117(4):433–42.
Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. Nat Metab 2021 310 [Internet]. 2021 Oct 14 [cited 2023 Sep 16];3(10):1302–12. Available from: https://www.nature.com/articles/s42255-021-00470-z
Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Vol. 47, International Journal of Molecular Medicine. Spandidos Publications; 2021.
Harisma R, Taofik D, Wathoni RN. Mesenchymal Stem Cell Secretome for Dermatology Application: A Review. 2021 [cited 2022 Nov 29]; Available from: https://doi.org/10.2147/CCID.S331044
Al-Azzawi B, McGuigan DH, Koivula FNM, Elttayef A, Dale TP, Yang Y, et al. The Secretome of Mesenchymal Stem Cells Prevents Islet Beta Cell Apoptosis via an IL-10-Dependent Mechanism. Open Stem Cell J. 2020 Mar 20;6(1):1–12.
Mrahleh M Al, Matar S, Jafar H, Wehaibi S, Aslam N, Awidi A. Human Wharton’s Jelly-Derived Mesenchymal Stromal Cells Primed by Tumor Necrosis Factor-α and Interferon-γ Modulate the Innate and Adaptive Immune Cells of Type 1 Diabetic Patients. Front Immunol. 2021 Sep 28;12:3906.
Novello S, Pellen-Mussi P, Jeanne S. Mesenchymal stem cell-derived small extracellular vesicles as cell-free therapy: Perspectives in periodontal regeneration. J Periodontal Res [Internet]. 2021 Jun 1 [cited 2021 Aug 17];56(3):433–42. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jre.12866
Arrigoni C, D’Arrigo D, Rossella V, Candrian C, Albertini V, Moretti M. Umbilical Cord MSCs and Their Secretome in the Therapy of Arthritic Diseases: A Research and Industrial Perspective. Cells 2020, Vol 9, Page 1343 [Internet]. 2020 May 28 [cited 2022 Mar 18];9(6):1343. Available from: https://www.mdpi.com/2073-4409/9/6/1343/htm
Thitilertdecha P, Lohsiriwat V, Poungpairoj P, Tantithavorn V, Onlamoon N. Extensive Characterization of Mesenchymal Stem Cell Marker Expression on Freshly Isolated and in Vitro Expanded Human Adipose-Derived Stem Cells from Breast Cancer Patients. Stem Cells Int. 2020;2020.
Al Naem M, Bourebaba L, Kucharczyk K, Röcken M, Marycz K. Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders. Stem Cell Rev Reports. 2020;16(2):301–22.
Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie. 2013 Dec;95(12):2196–211.
Marino L, Castaldi MA, Rosamilio R, Ragni E, Vitolo R, Fulgione C, et al. Mesenchymal stem cells from the Wharton’s jelly of the human umbilical cord: Biological properties and therapeutic potential. Int J Stem Cells. 2019;12(2):218–26.
Marwaha AK, Tan S, Dutz JP. Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. Clin Immunol. 2014 Sep 1;154(1):84–9.
Qi Y, Jiang D, Sindrilaru A, Stegemann A, Schatz S, Treiber N, et al. TSG-6 Released from Intradermally Injected Mesenchymal Stem Cells Accelerates Wound Healing and Reduces Tissue Fibrosis in Murine Full-Thickness Skin Wounds. J Invest Dermatol. 2014 Feb 1;134(2):526–37.
Katagiri W, Watanabe J, Toyama N, Osugi M, Sakaguchi K, Hibi H. Clinical Study of Bone Regeneration by Conditioned Medium from Mesenchymal Stem Cells after Maxillary Sinus Floor Elevation. Implant Dent [Internet]. 2017 Aug 1 [cited 2021 Aug 28];26(4):607–12. Available from: https://journals.lww.com/implantdent/Fulltext/2017/08000/Clinical_Study_of_Bone_Regeneration_by_Conditioned.19.aspx
Copyright (c) 2024 International Journal of Cell and Biomedical Science
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
